Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Ichor Awarded DARPA ADEPT: PROTECT Contract

by Global Biodefense Staff
November 18, 2014
Notable CBRN and Biodefense Contracts

Ichor Medical Systems of San Diego has been awarded a contract through the Defense Advanced Research Projects Agency (DARPA) and supported by the U.S. Army Research Office for up to $20.2 million of funding over five years, including a base period award of $8.6M.

The award is part of a DARPA program called Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT: PROTECT) aimed at developing new platform technologies that could be safely and rapidly deployed to the U.S. population and military personnel to provide immediate protection in the event of an infectious outbreak or biological weapons attack.

The program will fund the development and clinical assessment of Ichor’s TriGrid electroporation system as a DNA-based antibody delivery platform to produce protective antibodies for passive immunoprophylaxis.

While active immunization with traditional vaccines is effective at stimulating the immune system to generate protective antibodies, such responses are not immediate and may require multiple doses of the vaccine.

In contrast, the TriGrid technology could be used to bypass the immune system to directly deliver DNA sequences encoding protective antibodies into an infected or exposed individual. This approach would result in rapid production of antibodies by the individual providing immediate protection against the pathogen.

“We are excited for this new opportunity with the Department of Defense to apply the TriGrid technology to another area of high priority for national security,” said Bob Bernard, Ichor CEO. “Whether to address unknown bioterrorist threats or pandemic disease, success of this approach would revamp traditional vaccine processes and position the TriGrid favorably for use in other broad spectrum biodefense and pandemic applications.”

Source: Ichor press release, adapted. TriGrid is a trademarked, protected term by Ichor Medical Systems

Tags: AwardsDARPA

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy